MONTREAL--(BUSINESS WIRE)--SemaThera Inc. today announced the signing of a multi-year research collaboration and licensing agreement with Roche. The partnership will focus on developing SemaThera’s promising new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.
The field of diabetes is having its moment in the sun, as the American Diabetes Association 78th scientific sessions congress is currently taking place in Orlando, Florida.
SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan